30 August 2022, ATLANTA – The platform for neurological rehabilitation known as Neurofenix has raised USD 7 million in Series A funding. It uses sensors to improve patient outcomes. AlbionVC spearheaded this fundraising, with current investors, HTH, and InHealth Ventures also contributing. Due to the funding of US clinical trials, Neurofenix will be able to expand its product line and invest in its US expansion.
In the US, where 795,000 people have a stroke yearly, rehab expenses per patient can reach USD 17,000 or more. The only company in the market offering clinically-validated neuro-rehab along with patient-centric proprietary technologies to improve patient outcomes is Neurofenix.
Neurofenix’s CEO and co-founder, Guillem Singla Buxarrais, said:
“We have been creating our patient-centered sensor-based technology and platform to revolutionize neuro-rehab for the last six years. Previously, patients would not have had access to in-person physical or occupational therapy owing to insurance, financial, transportation, and health restrictions. This has shown to be transformative.”
Because of inadequate neurorehabilitation and a lack of occupational therapists, more than 75% of patients with the spinal cord, traumatic brain, and stroke injuries have long-term disabilities.
The patient-centered methodology utilized by Neurofenix combines telemedicine and sensor-based technology to tailor therapy and enhance recovery.
Guillem Singla Buxarrais (CEO) and Dimitrios Athanasiou, both Entrepreneur First alumni from Imperial College, founded the company in 2016. (CTO)
Through its NeuroBallTM platform, Neurofenix’s rehabilitation program focuses on arm and hand therapy. The instrument, which was developed with input from more than 300 patients and therapists, is tailored to each patient based on their needs and enables them to carry out more difficult, repetitive actions to increase strength.
Because of the sophisticated sensors that may be used by patients with impairments, and the wi-fi-connected app contains games and activities to encourage patients to use it frequently. They are motivated to carry on by leaderboards and real-time feedback. In three different studies conducted at Brunel University London between 2017 and 2021, patients could perform 20 times as many movement repetitions at home using the portable platform as they could with other techniques.
Through its NeuroBallTM platform, Neurofenix’s rehabilitation program focuses on arm and hand therapy. With input from more than The exclusive portal, which permits remote patient monitoring, is well-liked by occupational therapists in the US who have grown more confident in the use of digital care delivery through Covid-19.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
